A Phase 2, Non-controlled, Open-Label, Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2017
Price : $35 *
At a glance
- Drugs Setrusumab (Primary)
- Indications Osteogenesis imperfecta
- Focus Therapeutic Use
- Acronyms METEOROID
- Sponsors Mereo BioPharma
- 21 Dec 2017 Status changed from recruiting to withdrawn prior to enrolment.
- 06 Oct 2017 Status changed from not yet recruiting to recruiting.
- 17 Jul 2017 New trial record